Key result
Dipyridamole increases the LF ratio ~5-fold in angina patients compared to healthy controls.
Why the study?
Only a few studies have reported spectral modifications of heart rate variability during myocardial ischemia in humans, limiting understanding of autonomic changes.
Does dipyridamole infusion induce different changes in heart rate variability in patients with angina compared to healthy controls?
Case-Control (n=38)
Does dipyridamole infusion induce different changes in heart rate variability in patients with angina compared to healthy controls?
Heart rate variability analysis, specifically the LF ratio during dipyridamole infusion, can help discriminate patients with myocardial ischemia from healthy controls.
Answers are grounded in this paper and cite their sources.
May aid noninvasive ischemia detection; hypothesis-generating and requires prospective validation before clinical adoption.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Kim et al. (2003) conducted a case-control in Stable or unstable angina (n=38). Dipyridamole infusion vs. Healthy controls was evaluated on LF ratio (ratio of the LF power at peak stress and in the basal state) (p=<0.001). Dipyridamole infusion significantly increased the LF ratio in angina patients (2.84) compared to a decrease in healthy controls (0.55) (p<0.001), effectively discriminating between the groups.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: